Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565041 | 0.84 | PTGDR2 (0.51) | PTGDR2MAPTL3MBTL1GLAELANE | |
| SCHEMBL14526124 | 0.83 | ALDH1A1 (0.48) | MAPTHTTMEN1KMT2A | |
| SCHEMBL16951980 | 0.83 | HTT (0.50) | MAPTL3MBTL1HTT | |
| SCHEMBL5646670 | 0.82 | PPARD (0.52) | PTGDR2MAPTPKM | |
| SCHEMBL7867819 | 0.81 | POLB (0.60) | PTGDR2MAPTHTTMEN1KMT2A | |
| SCHEMBL5404749 | 0.80 | TSHR (0.58) | PTGDR2MAPTL3MBTL1GLA | |
| SCHEMBL16342279 | 0.80 | PTGDR2 (0.60) | PTGDR2MAPTL3MBTL1GLAPKM | |
| SCHEMBL4655073 | 0.80 | ELANE (0.56) | PTGDR2MAPTL3MBTL1GLAELANE | |
| SCHEMBL8591037 | 0.79 | PTGDR2 (0.53) | PTGDR2MAPTL3MBTL1GLAELANE | |
| SCHEMBL5699506 | 0.79 | PTGDR2 (0.77) | PTGDR2MAPTL3MBTL1GLAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199239-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060074111-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1513795-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000762-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074111-A1 | Chemical compounds | HDAC3, HAT1, H1-3 | PTGDR2 4016/4885MAPT 3846/4885L3MBTL1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.